Phase II trial of single agent ZD1839 (Iressa) [gefitinib] in poor performance status patients with previously untreated advanced non-small cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2013
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 May 2011 Actual end date (Sep 2005) added as reported by ClinicalTrials.gov.
- 02 Oct 2007 Status changed from in progress to completed.
- 13 Nov 2005 New trial record.